# NOV 3 0 2005

# 510(k) SUMMARY

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

The assigned51o(k)um: K5320

The purpose of this 510(k) submission is to expand the Analytical Reactivity claims of the currently 510(k) cleared BinaxNOW® Influenza A & B Test (510(k) #K041049).

# SUBMITTER

Binax, Inc. 10 Southgate Road Scarborough, Maine 04074 (207) 730-5700 (Office) (207) 730-5710 (FAX)

CONTACT PERSON   
Angela Drysdale   
angela.drysdale@binax.com (email)

DATE PREPARED November 04, 2005

TRADE NAME BinaxNOW® Influenza A & B Test

COMMON NAME   
$N O W ^ { \circledast }$ Ftu A/B Test, $N O W ^ { \circledast }$ Influenza AB, NOW® Influenza A & B, Binax NOW® Influenza A & B,   
Binax NOW® Influenza AVB

CLASSIFICATION NAME Antigen, CF (including CF Controls), Influenza Virus A, 8, C (per 21 CFR 866.3330)

PREDICATE DEVICES Binax NOW® Influenza A & B Test; K041049 Binax NOW® Flu A Test; K021649 Binax NOW® Flu B Test; K021646

# DEVICE DESCRIPTION:

The BinaxNOw® Influenza A & B Test is an immunochromatographic membrane assay that uses highly sensitive monoclonal antibodies to detect influenza type A & B nucleoprotein antigens in nasopharyngeal specimens. These antibodies and a control antibody are immobilized onto a membrane support as three distinct lines and combined with other reagents/pads to construct a test strip. This test strip is mounted inside a cardboard, bookshaped hinged test device.

Swab specimens require a sample preparation step, in which the sample is eluted off the swab into elution solution or transport media. Nasal wash/aspirate samples require no preparation. Sample is added to the top of the test strip and the test device is closed. Test results are interpreted at 15 minutes based on the presence or absence of pink-to-purple colored Sample Lines. The blue Control Line turns pink in a valid assay.

# INTENDED USE

The BinaxNOw® Influenza A & B Test is an in vitro immunochromatographic assay for the qualitative detection of influenza A and B nucleoprotein antigens in nasopharyngeal swab and nasal wash/aspirate specimens. It is intended to aid in the rapid differential diagnosis of influenza A and B viral infections. Negative test results should be confirmed by culture.

# TECHNOLOGICAL CHARACTERISTICS

The Expanded Claim BinaxNOw® Influenza A & B Test is exactly the same as the currently $5 1 0 ( { \sf k } )$ cleared BinaxNOw® Influenza A & B Test. Both tests use identical lateral flow immunochromatographic technology. Both tests are rapid immunoassays that employ specific antibodies immobilized onto a solid phase to capture and visualize influenza nucleoprotein antigens.

# PERFORMANCE SUMMARY

CLINICAL STUDIES

BinaxNOW® Influenza A & B Test Perforance vs. Cell Culture / DFA  Prospective Study

The performance of the BinaxNOw® Influenza A $\&$ B Test was compared to cell culture and/or DFA, and to the Binax $N O W ^ { \circledast }$ Flu A Test and the Binax NOW® Flu B Test, in a prospective study conducted in 2004 outside the US. Nasopharyngeal (NP) swab and nasal wash / aspirate specimens, collected at multiple sites from children (less than 18 years of age) and adults (18 years or older) presenting with influenza-like symptoms, were evaluated in the Binax test at a central testing lab.

Forty-seven percent $( 4 7 \% )$ of the population tested was male, $53 \%$ female, $40 \%$ pediatric $( < 1 8$ years), and $60 \%$ adult $( \geq 1 8$ years). No differences in test performance were observed based on patient age or gender. There were no invalid tests reported.

One hundred and thirteen (113) NP swab specimens and 1 wash/aspirate specimen were tested. One hundred and eight (108) of the 114 samples tested were influenza negative by culture/DFA, and 6 samples were influenza positive. When compared to culture/DFA, the BinaxNOW® Test was $7 5 \%$ $( 3 / 4 )$ sensitive and $100 \%$ (110/110) specific for detection of influenza A and $50 \%$ (1/2) sensitive and $100 \%$ (112/1 12) specific for detection of influenza B. There was $100 \%$ agreement between the BinaxNOw® Influenza A & B Test and the individual Flu A and Flu B Tests.

BinaxNOW® A & B Test specificity by sample type versus cell culture / DFA, including $9 5 \%$ confidence intervals, is listed below.

BinaxNOw® Influenza A & B Test Specificity vs. Cell Culture/DFA   

<table><tr><td rowspan=1 colspan=4>FLUB SPECIFICITY</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>% Spec</td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>111</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>97-100%</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>16-99%</td></tr><tr><td rowspan=1 colspan=1>112</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>97-100%</td></tr></table>

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4>FLU A SPECIFICITY</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+/180</td><td rowspan=1 colspan=1>% Spec</td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>NP Swab</td><td rowspan=1 colspan=1>109</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>97-100%</td></tr><tr><td rowspan=1 colspan=1>Wash/Aspirate</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>16-99%</td></tr><tr><td rowspan=1 colspan=1>Overall</td><td rowspan=1 colspan=1>110</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>97-100%</td></tr></table>

BinaxNOW® Influenza A & B Test Performance vs. Binax NOW® Flu A and Flu B Tests:

Performance of the BinaxNOw® Influenza A & B Test was compared to the current $N O W ^ { ( \alpha ) }$ Flu A Test on 306 retrospective frozen clinical samples and to the $N O W ^ { \mathcal { \left( B \right) } }$ Flu B Test on 303 retrospective frozen clinical samples. All clinical samples were collected from symptomatic patients at multiple physician offices, clinics and hospitals located in the Southern, Northeastern and Midwestern regions of the United States and from one hospital in Sweden. Fifty-three percent $( 5 3 \% )$ of the population tested was male, $47 \%$ female, $64 \%$ pediatric $X 1 8$ years) and $3 6 \%$ adult $( \geq 1 8$ years). Nasal wash/aspirate specimens comprised approximately $5 7 \%$ of the samples tested, while NP swabs represented $42 \%$ . No differences in test performance were observed based on patient age and gender or based on sample type tested.

The BinaxNOW® Influenza A & B Test was $100 \%$ sensitive and $9 6 \%$ specific for detection of influenza A vs. the $N O W ^ { \circledast }$ Flu A Test and $9 3 \%$ sensitive and $9 7 \%$ specific for detection of influenza B vs. the $N O W ^ { \textcircled { 8 } }$ Flu B Test. Test performance by virus type (A vs. B), by sample type (swab vs. wash/aspirate), and overal, including $9 5 \%$ confidence intervals, is detailed in the following tables.

# BinaxNOw® Influenza A & B Test vs. NOW® Flu A Test for Detection of Influenza A

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4>FLU A SENSITIVITY</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>+/*</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>%Sens</td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>NP Swab</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>89-100%</td></tr><tr><td rowspan=1 colspan=1>Wash/Aspirate</td><td rowspan=1 colspan=1>47</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>93-100%</td></tr><tr><td rowspan=1 colspan=1>Overall</td><td rowspan=1 colspan=1>77</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>95-100%</td></tr></table>

<table><tr><td rowspan=1 colspan=1>WRY</td><td rowspan=1 colspan=3>FLU A SPECIFICITY</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>% Spec</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>96</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>99%</td><td rowspan=1 colspan=1>94-100%</td></tr><tr><td rowspan=1 colspan=1>123</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>93%</td><td rowspan=1 colspan=1>88-96%</td></tr><tr><td rowspan=1 colspan=1>219</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>96%</td><td rowspan=1 colspan=1>88-96%</td></tr></table>

# BinaxNOw® Influenza A & B Test vs. NOW® Flu B Test for Detection of Influenza B

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4>FLUBSENSITIVITY</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>+/+.,</td><td rowspan=1 colspan=1>-+</td><td rowspan=1 colspan=1>% Sens</td><td rowspan=1 colspan=1>95%C1</td></tr><tr><td rowspan=1 colspan=1>NP Swab</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>29-99%</td></tr><tr><td rowspan=1 colspan=1>WashvAspirate</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>92%</td><td rowspan=1 colspan=1>66-98%</td></tr><tr><td rowspan=1 colspan=1>Overall</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>93%</td><td rowspan=1 colspan=1>70-98%</td></tr></table>

<table><tr><td rowspan=1 colspan=4>FLU B SPECIFICITY</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+7</td><td rowspan=1 colspan=1>% Spec</td><td rowspan=1 colspan=1>95%CI</td></tr><tr><td rowspan=1 colspan=1>126</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>99%</td><td rowspan=1 colspan=1>96-100%</td></tr><tr><td rowspan=1 colspan=1>152</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>94%</td><td rowspan=1 colspan=1>90-97%</td></tr><tr><td rowspan=1 colspan=1>278</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>97%</td><td rowspan=1 colspan=1>94-98%</td></tr></table>

# Binax NOW® Flu A and Flu B Test Performance vs. Cell Culture

Performance of the Binax $N O W ^ { \textregistered }$ Flu A and Flu B Tests was compared to cell culture on 373 prospective clinical samples collected as part of a multi-center study conducted during the 2002 Flu season at physician offices and clinics located in the Western and mid-Atlantic United States. Fifty-four percent $( 5 4 \% )$ of the population tested was male, $46 \%$ female, $90 \%$ pediatric (< 18 years) and $10 \%$ adult $( \geq 1 8$ years). Nasal wash/aspirates comprised $51 \%$ of the samples tested, while NP swabs represented $49 \%$ . No differences in performance were observed based on patient age and gender or based on sample type tested.

The Binax NOW® Flu A Test was $80 \%$ sensitive and $93 \%$ specific while the Binax $N O W ^ { \otimes }$ Flu B Test was $6 5 \%$ sensitive and $9 7 \%$ specific when compared to cell culture. The performance of the two tests by sample type (swab vs. wash/aspirate) and overall, including $9 5 \%$ confidence intervals, is detailed in the following tables.

Binax NOW® Flu A Test vs. Cell Culture   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4>FLU A SENSITIVITY</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>: +1+</td><td rowspan=1 colspan=1>$\}$</td><td rowspan=1 colspan=1>% Sens</td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>NP Swab</td><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>78%</td><td rowspan=1 colspan=1>62-88%</td></tr><tr><td rowspan=1 colspan=1>Wash/Aspirate</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>82%</td><td rowspan=1 colspan=1>69-90%</td></tr><tr><td rowspan=1 colspan=1>Overall</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>80%</td><td rowspan=1 colspan=1>71-87%</td></tr></table>

<table><tr><td rowspan=1 colspan=4>FLU A SPECIFICITY</td></tr><tr><td rowspan=1 colspan=1>$\</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>% Spec</td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>133</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>92%</td><td rowspan=1 colspan=1>86-95%</td></tr><tr><td rowspan=1 colspan=1>133</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>94%</td><td rowspan=1 colspan=1>89-97%</td></tr><tr><td rowspan=1 colspan=1>266</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>93%</td><td rowspan=1 colspan=1>89-95%</td></tr></table>

Binax NOW® Flu B Test vs. Cell Culture   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4>FLU B SENSITIVITY</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>+1+</td><td rowspan=1 colspan=1>1+</td><td rowspan=1 colspan=1>x Sens</td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>NP Swab</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>58%</td><td rowspan=1 colspan=1>42-73%</td></tr><tr><td rowspan=1 colspan=1>Wash/Aspirate</td><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>71%</td><td rowspan=1 colspan=1>5683%</td></tr><tr><td rowspan=1 colspan=1>Overall</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>65%</td><td rowspan=1 colspan=1>54-75%</td></tr></table>

<table><tr><td rowspan=1 colspan=4>FLU B SPECIFICITY</td></tr><tr><td rowspan=1 colspan=1>1-</td><td rowspan=1 colspan=1>+/</td><td rowspan=1 colspan=1>:% Spec</td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>142</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>97%</td><td rowspan=1 colspan=1>93-99%</td></tr><tr><td rowspan=1 colspan=1>146</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>97%</td><td rowspan=1 colspan=1>93-99%</td></tr><tr><td rowspan=1 colspan=1>288</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>97%</td><td rowspan=1 colspan=1>95-99%</td></tr></table>

# ANALYTICAL STUDIES

# Analytical Sensitivity

The BinaxNOw® test limit of detection (LOD), defined as the concentration of influenza virus that produces positive BinaxNOw® test results approximately $95 \%$ of the time, was identified by evaluating different concentrations of inactivated Flu A/Beijing and inactivated Flu B/Harbin in the BinaxNOW® test.

Twelve (12) different operators each interpreted 2 devices run at each concentration for a total of 24 determinations per level. The following results identify a concentration of $1 . 0 3 \times 1 0 ^ { 2 }$ ng/ml as the LOD for Fiu A/Beijing and ${ \tt 6 . 0 5 \times 1 0 ^ { 1 } }$ ng/ml for Flu B/Harbin.

<table><tr><td rowspan=1 colspan=3>Influenza A/Bejing</td></tr><tr><td rowspan=1 colspan=1>Concentration(ng/m)</td><td rowspan=1 colspan=1>#Detected</td><td rowspan=1 colspan=1>%Detected</td></tr><tr><td rowspan=1 colspan=1>1.03 x 10 (LOD)</td><td rowspan=1 colspan=1>23/24</td><td rowspan=1 colspan=1>96</td></tr><tr><td rowspan=1 colspan=1>5.60 x 10&#x27; (Cutoff)</td><td rowspan=1 colspan=1>*</td><td rowspan=1 colspan=1>50</td></tr><tr><td rowspan=1 colspan=1>3.27 x 10&#x27; (High Neg)</td><td rowspan=1 colspan=1>4/24</td><td rowspan=1 colspan=1>17</td></tr><tr><td rowspan=1 colspan=1>True Negative</td><td rowspan=1 colspan=1>0/24</td><td rowspan=1 colspan=1>0</td></tr></table>

s asaulauatnhc  hs oce uAV/Beijing.

<table><tr><td rowspan=1 colspan=3>Intluenza B/Harbin</td></tr><tr><td rowspan=1 colspan=1>Concentration(ng/m)</td><td rowspan=1 colspan=1>#Detected</td><td rowspan=1 colspan=1>%Detected</td></tr><tr><td rowspan=1 colspan=1>6.05 x 10&#x27; (LOD)</td><td rowspan=1 colspan=1>23/24</td><td rowspan=1 colspan=1>96</td></tr><tr><td rowspan=1 colspan=1>2.42x 10&#x27; (Cutoff)</td><td rowspan=1 colspan=1>11/24</td><td rowspan=1 colspan=1>46</td></tr><tr><td rowspan=1 colspan=1>1.51 x 10&#x27; (High Neg)</td><td rowspan=1 colspan=1>6/24</td><td rowspan=1 colspan=1>25</td></tr><tr><td rowspan=1 colspan=1>True Negative</td><td rowspan=1 colspan=1>0/24</td><td rowspan=1 colspan=1>0</td></tr></table>

To demonstrate comparable analytical sensitivity of the BinaxNOw® Influenza A & B Test and the individual $N O W ^ { \mathbf { \otimes } }$ Flu A and Flu B Tests, the Flu A and B cutoff levels identified above were evaluated in the $N O W ^ { \infty }$ Flu A and Flu B Tests.

The A/Beijing cutoff sample detected $50 \%$ of the time in the BinaxNOW® influenza A & B Test was also detected $50 \%$ (12/24) of the time in the NOW® Flu A Test when tested by six (6) operators interpreting a total of 24 devices. Likewise, the B/Harbin cutoff sample detected $40 \%$ of the time in the BinaxNOw® Influenza A & B Test was detected $10 \%$ (4/40) of the time in the NOW® Flu B Test when tested by ten (10) operators interpreting 40 devices.

These data demonstrate that the analytical sensitivity of the BinaxNOw® Influenza A & B Test is equivalent or better than that of the individual NOW® Flu A and B Tests.

The two (2) live avian influenza (H5N1) strains isolated from humans listed below tested positive in the BinaxNOW® influenza A & B Test at concentrations ranging from $1 0 ^ { 2 } { - } 1 0 ^ { 4 } \mathrm { T C I D } _ { 5 0 } / \mathrm { m i }$ .

Avian Influenza Strain AHong Kong/156/97 AVietnam/1194/04

Concentration 1.3 x 10^2 1.0 x 104

# Reactivity Testing

The seven $( 7 )$ live influenza A strains and five (5) live influenza B strains listed below tested positive in the BinaxNOW® Influenza A & B Test at concentrations ranging from $1 0 ^ { 2 } - 1 0 ^ { 6 }$ EPY $C E | \textcircled { 1 } 5 0 / m |$ , Although the specific influenza strains causing infection in humans can vary year to year, all contain the conserved nucleoproteins targeted by the BinaxNOw® test.'

Influenza Strain ATCC#   
Flu AWS/33 VR-825   
Flu A/NWS/33 VR-219   
Flu AHong Kong/8/68 VR-544   
Flu A/Aichi/2/68 VR-547   
Flu A/New Jersey/8/76 VR-897   
Flu A/MaV302/54 VR-98   
Flu A/Port Chalmers/1/73 VR-810   
Flu B/Lee/40 VR-101   
Flu B/Brigit VR-786   
Flu B/Russia/69 VR-790   
Flu B/Hong Kong/5/72 VR-791   
Flu B/R75 VR-789

# Analytic Specificity (Cross-Reactivity)

To determine the analytical specificity of the BinaxNOw® Influenza A & B Test, 36 commensal and pathogenic microorganisms (27 bacteria, 8 viruses and 1 yeast) that may be present in the nasal cavity or nasopharynx were tested. All of the following microorganisms were negative when tested at concentrations ranging from $1 0 ^ { 4 }$ to $1 0 ^ { 8 }$ TCIDso/ml (viruses), $1 0 ^ { 7 }$ to $1 0 ^ { 8 }$ E organisms/ml (bacteria) and $1 0 ^ { 6 }$ organisms/ml (yeast).

Bacteria   
Acinetobacter   
Bordetella pertussis   
Enterococcus faecalis   
Escherichia coli   
Gardnerella vaginalis   
Haemophilus influenzae   
Klebsiella pneumoniae   
Lactobacillus casei   
Legionella pneumophila   
Listeria monocytogenes   
Moraxella catarrhalis   
Neisseria gonorrhoeae   
Neisseria meningitidis   
Neisseria sicca   
Neisseria subflava   
Proteus vuigaris   
Pseudomonas aeruginosa   
Serratia marcescens   
Staphylococcus aureus   
Staphylococcus aureus   
(Cowan prolein A producing strain   
Staphylococcus epidermidis   
Streptococcus, Group A   
Streptococcus, Group B   
Virusess   
Adenovirus   
Coronavirus   
Coxsackie B4   
Cytomegalovirus (CMV)   
Parainfluenza 1   
Parainfluenza 2   
Parainfluenza 3   
Respiratory Syncytial Virus (RSV)

Yeast Candida albicans

Streptococcus, Group C Streptococcus, Group F Streptococcus mutans Streptococcus pneumoniae

# Interfering Substances

The following substances, naturally present in respiratory specimens or that may be artificially introduced into the nasal cavity or nasopharynx, were evaluated in the BinaxNOw® Influenza A & B Test at the concentrations listed and were found not to affect test performance. Whole blood $( 1 \% )$ did not interfere with the interpretation of negative BinaxNOw® test results, but did interfere with the interpretation of Flu A LOD positive samples. Therefore, visibly bloody samples may not be appropriate for use in this test.

Substance   
1 OTC mouthwash   
3 OTC nasal sprays   
3 OTC throat drops   
2 OTC throat sprays   
4-acetamidophenol   
Acetylsalicylic acid   
Albuterol   
Chlorpheniramine   
Dextromethorphan   
Diphenhydramine   
Guaiacol glycerol ether   
Oxymetazoline   
Phenylephrine   
Phenylpropanolamine   
Rebetol   
Relenza   
Rimantadine   
Synagis   
Tamiflu

Concentration   
20%   
15%.   
15%   
20%   
10 mg/ml   
15 mg/ml   
20 mg/ml   
5 mg/ml   
10 mg/ml   
5 mg/ml   
20 mg/ml   
0.05%   
50 mg/ml   
20 mg/ml   
500 ng/ml   
20 mg/ml   
500 ng/ml   
0.1 mg/ml   
50 ma/ml

# Transport Media

The following transport media were tested in the BinaxNOW® Influenza A & B Test as negative samples (no virus present) and after inoculation with the LOD levels of Influenza A & B. Media did not impact BinaxNow® test perfomance, with the media alone testing negative in the NOW test and media inoculated with LOD Influenza A & B testing positive on the appropriate test line in BinaxNOW® test.

Amies Media   
Hank's Balanced Salt Solution   
M4 Media   
M4-RT Media   
M5 Media   
Stuart's Media   
Saline

# Reproducibility

A blind study of the BinaxNOw® Influenza A & B Test was conducted at 3 separate sites using panels of blind coded specimens containing negative, low positive, and moderate positive samples. Participants tested each sample multiple times on 3 different days. There was $97 \%$ EY (242/250) agreement with expected test results, with no significant differences within run (replicates tested by one operator), between run (3 different days) or between sites (3 sites).

eW.enal..ole zVir6a M edition, In Lennette, et. AIl (ed.). American Society for Microbiology, Washington, D.C.

# NOV 3 0 2005

Ms. Angela Drysdale Clinical Affairs Specialist Binax, Inc. 10 Southgate Road Portland, Maine 04103

Re: k053126 Trade/Device Name: BinaxNOW® Influenza A & B Test Regulation Number: 21 CFR 866.3330 Regulation Name: Influenza Virus Serological Reagents Regulatory Class: Class II Product Code: GNX Dated: November 4, 2005 Received: November 7, 2005

Dear Ms. Drysdale:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2-

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240)276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address   
http://www.fda.gov/cdrb/industry/support/index.html

Sincerely yours,

$$
\sin a \pi , a \pi \pi \pi
$$

Sally A. Hojvat, M.Sc., Ph.D.   
Director   
Division of Microbiology Devices Office of In Vitro Diagnostic Device Evaluation and Safety   
Center for Devices and   
Radiological Health

510(k) Number (if known):

K0531246

Device Name: BinaxNOW® Influenza A & B Test

Indications For Use:

The BinaxNOw® Influenza A & B Test is an in vitro immunochromatographic assay for the qualitative detection of influenza A and 8 nucleoprotein antigens in nasopharyngeal (NP) swab and nasal wash/aspirate specimens. It is intended to aid in the rapid differential diagnosis of influenza A and B viral infections. Negative test results should be confirmed by culture.

PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

(Per 21 CFR 801.109) (Optional Format 1-2-96)